Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>=18 years, either sex, any race.
Eastern Cooperative Oncology Group performance status of 0, 1, or 2.
There must be no known standard therapy, or disease must be refractory to standard therapy
Adequate hematologic, renal, and hepatic organ function and laboratory parameters
For advanced solid tumors, non-Hodgkin's lymphoma, or multiple myeloma:
* Participants must have histologically proven solid tumors, non-Hodgkin's lymphoma, or multiple myeloma.
* Evaluable malignancy must be present by computed tomography or magnetic resonance imaging, obtained within 4 weeks prior to the start of treatment with SCH 727965.
Subjects with multiple myeloma must have measurable disease defined as:
* Serum monoclonal protein greater than 0.5 g/dL or urine light chain excretion of greater than 0.2 g/24-hour obtained within 4 weeks prior to the start of treatment.
* serum free light chain ratio greater than 5 times the normal ratio limit; and/or
* measurable soft tissue plasmacytoma greater than 2 cm, by either physical examination and/or applicable radiographs; and/or
* bone marrow involvement greater than 30%.
For B-cell chronic lymphocytic leukemia (B-CLL):
* Diagnosis of B-CLL according to the National Cancer Institute Working Group (NCI-WG) criteria or a histological diagnosis of small lymphocytic lymphoma.
* Disease must be evaluable according to NCI-WG response criteria.
You may not be if
Symptomatic brain metastases or primary central nervous system malignancy.
Previous radiation therapy to \>25% of the total bone marrow.
Previous treatment with SCH 727965.
Known HIV infection.
Clareo Health | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
